Jeffrey Hessekiel Sells 25,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 25,000 shares of Exelixis stock in a transaction on Monday, October 28th. The shares were sold at an average price of $28.39, for a total transaction of $709,750.00. Following the completion of the transaction, the executive vice president now owns 580,325 shares in the company, valued at approximately $16,475,426.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Jeffrey Hessekiel also recently made the following trade(s):

• On Monday, September 23rd, Jeffrey Hessekiel sold 25,000 shares of Exelixis stock. The shares were sold at an average price of $26.38, for a total value of $659,500.00.
• On Monday, August 26th, Jeffrey Hessekiel sold 20,000 shares of Exelixis stock. The shares were sold at an average price of $25.79, for a total value of $515,800.00.

Exelixis Stock Up 12.9 %

Shares of EXEL traded up $3.71 during trading hours on Wednesday, reaching $32.44. 6,737,999 shares of the company traded hands, compared to its average volume of 2,047,408. The stock has a fifty day simple moving average of $26.81 and a 200 day simple moving average of $24.15. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $33.32. The stock has a market capitalization of $9.25 billion, a PE ratio of 27.97, a price-to-earnings-growth ratio of 0.61 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The business had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. Research analysts predict that Exelixis, Inc. will post 1.58 EPS for the current fiscal year.

Analysts Set New Price Targets

EXEL has been the topic of a number of analyst reports. BMO Capital Markets lifted their price objective on shares of Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 price target on shares of Exelixis in a research note on Wednesday. Bank of America raised their price objective on shares of Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Finally, The Goldman Sachs Group raised Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.44.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. V Square Quantitative Management LLC purchased a new position in shares of Exelixis during the 3rd quarter worth about $30,000. Park Place Capital Corp acquired a new position in shares of Exelixis in the 2nd quarter valued at $45,000. GAMMA Investing LLC grew its stake in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 1,041 shares during the period. EntryPoint Capital LLC increased its holdings in shares of Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,746 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Exelixis in the 3rd quarter worth $74,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.